Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Innovating on Numerous Fronts with DehydraTECH Drug Delivery Platform
- Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds
- The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods
- Its DehydraTECH technology has potential applications for nicotine absorption
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Its DehydraTECH drug delivery platform fosters healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. The company’s process changes the way edible cannabinoids enter the body (http://nnw.fm/8uGHp). A drug delivery innovator, Lexaria Bioscience is headquartered in Kelowna, British Columbia.
Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. In essence, the company disrupts the manner in which cannabinoids enter the bloodstream through the gastrointestinal tract (http://nnw.fm/Fq0to). Lexaria’s emphasis on oral ingestion provides a practical and often healthier option to other delivery methods for bioactive substances used extensively today. This includes inhalational delivery via smoking.
The DehydraTECH platform masks taste, lessens the time of onset and increases bio-absorption by 5-10 times. The technology is patent protected for cannabidiol and all other non-psychoactive cannabinoids. Lexaria has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. These patents apply to manifold consumer/pharma product dosage forms and include food liquid emulsions, capsules, tablets and more.
The Lexaria Hemp Co. holds exclusive international rights to the Lexaria patent portfolio related to hemp-based applications. Moreover, its Canadian subsidiary, Lexaria CanPharm Corp., owns exclusive international rights to Lexaria’s intellectual property that’s applicable to psychotropic bioactive molecules, which act upon human CB1 and CB2 receptors in those global geographic areas where it is permissible to do so (http://nnw.fm/9rbML).
Lexaria Bioscience’s business model involves developing and out-licensing its DehydraTECH platform to third-party partners/distributors (http://nnw.fm/n1eJ1). In addition, its business model involves the sale of Lexaria-developed and joint venture products. The company’s product sales include hemp oil-based CBD (cannabidiol) offerings. Its TurboCBD hemp oil capsules contain ginseng and ginkgo to promote better focus and memory and have been evaluated in clinical tests.
Lexaria’s product sales additionally include ViPova-branded premium teas. These teas deliver cannabidiol in a number of flavors and have been available for several years, showcasing Lexaria’s leadership position in beverage formulations.
Lexaria Bioscience has a collaborative research agreement with Canada’s National Research Council. This research agreement is to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions (http://nnw.fm/LY6fD).
Lexaria Bioscience has engaged in research regarding the use of its technology for nicotine absorption, relating to the nicotine industry. It has partnered, via wholly owned subsidiary Lexaria Nicotine LLC, with one of the world’s largest tobacco companies to drive innovation in oral, reduced risk nicotine consumer products using the patented DehydraTECH drug delivery platform (http://nnw.fm/RC2Ib). Lexaria Nicotine aims to perform a wide-ranging series of clinical investigations of oral forms of nicotine delivery, funded by its partner, employing Lexaria’s patented DehydraTECH technology.
Lexaria Bioscience continues its R&D for the improved delivery of bioactive compounds. The company offers investors the potential to earn ROI from its disruptive technology in the emerging market of low cost edibles. Lexaria continues to advance its technology that enables consumer benefits and the lowest cost-per-serving.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Lexaria Bioscience is focusing on its unique technology for the delivery of bioactive compounds
- The company’s concentration on oral ingestion results in an option that often healthier than other delivery methods
- Its DehydraTECH technology has potential applications for nicotine absorption
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) focuses on technology for the improved delivery of bioactive compounds. Its DehydraTECH drug delivery platform fosters healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. The company’s process changes the way edible cannabinoids enter the body (http://nnw.fm/8uGHp). A drug delivery innovator, Lexaria Bioscience is headquartered in Kelowna, British Columbia.
Lexaria’s technology has been shown to be effective in numerous global studies, significantly assisting rapidity and quantity of absorption for a range of lipophilic (fat-soluble), bioactive molecules. In essence, the company disrupts the manner in which cannabinoids enter the bloodstream through the gastrointestinal tract (http://nnw.fm/Fq0to). Lexaria’s emphasis on oral ingestion provides a practical and often healthier option to other delivery methods for bioactive substances used extensively today. This includes inhalational delivery via smoking.
The DehydraTECH platform masks taste, lessens the time of onset and increases bio-absorption by 5-10 times. The technology is patent protected for cannabidiol and all other non-psychoactive cannabinoids. Lexaria has patents pending for THC, nonsteroidal anti-inflammatory drugs (NSAIDs), nicotine, other psychoactive cannabinoids and other molecules. These patents apply to manifold consumer/pharma product dosage forms and include food liquid emulsions, capsules, tablets and more.
The Lexaria Hemp Co. holds exclusive international rights to the Lexaria patent portfolio related to hemp-based applications. Moreover, its Canadian subsidiary, Lexaria CanPharm Corp., owns exclusive international rights to Lexaria’s intellectual property that’s applicable to psychotropic bioactive molecules, which act upon human CB1 and CB2 receptors in those global geographic areas where it is permissible to do so (http://nnw.fm/9rbML).
Lexaria Bioscience’s business model involves developing and out-licensing its DehydraTECH platform to third-party partners/distributors (http://nnw.fm/n1eJ1). In addition, its business model involves the sale of Lexaria-developed and joint venture products. The company’s product sales include hemp oil-based CBD (cannabidiol) offerings. Its TurboCBD hemp oil capsules contain ginseng and ginkgo to promote better focus and memory and have been evaluated in clinical tests.
Lexaria’s product sales additionally include ViPova-branded premium teas. These teas deliver cannabidiol in a number of flavors and have been available for several years, showcasing Lexaria’s leadership position in beverage formulations.
Lexaria Bioscience has a collaborative research agreement with Canada’s National Research Council. This research agreement is to investigate opportunities associated with bioavailability enhancement of lipophilic active ingredient compositions (http://nnw.fm/LY6fD).
Lexaria Bioscience has engaged in research regarding the use of its technology for nicotine absorption, relating to the nicotine industry. It has partnered, via wholly owned subsidiary Lexaria Nicotine LLC, with one of the world’s largest tobacco companies to drive innovation in oral, reduced risk nicotine consumer products using the patented DehydraTECH drug delivery platform (http://nnw.fm/RC2Ib). Lexaria Nicotine aims to perform a wide-ranging series of clinical investigations of oral forms of nicotine delivery, funded by its partner, employing Lexaria’s patented DehydraTECH technology.
Lexaria Bioscience continues its R&D for the improved delivery of bioactive compounds. The company offers investors the potential to earn ROI from its disruptive technology in the emerging market of low cost edibles. Lexaria continues to advance its technology that enables consumer benefits and the lowest cost-per-serving.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
